Can an arthritis drug quiet the pain of chronic pancreatitis?

NCT ID NCT06426160

Ongoing Symptom relief Sponsor: Soren Schou Olesen Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests whether tocilizumab, an anti-inflammatory drug used for arthritis, can reduce pain and improve quality of life in people with chronic pancreatitis. Participants receive either tocilizumab or a placebo every four weeks for 24 weeks. The study measures changes in pain scores and overall well-being to see if the drug offers meaningful relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tocilizumab (an anti-inflammatory drug that blocks interleukin-6 receptors)
What this could lead to: If effective, tocilizumab could offer a new way to reduce chronic pain and improve daily functioning for people with chronic pancreatitis.
What could go wrong: This is a small, early-stage trial. The drug may not outperform placebo, and tocilizumab carries risks like infection and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATITIS, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic pancreatitis Digestive System Diseases Inflammation pancreas disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATITIS, CHRONIC

Contacts and locations

Locations

Centre for Pancreatic Diseases and Mech-Sense research laboratory, Aalborg University Hospital

Aalborg, North Denmark, 9000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.